The cancer drug tazemetostat (Tazverik) is being voluntarily withdrawn in the U.S. and all other markets over concerns about secondary cancers, drugmaker Ipsen announced. The company also said it is ...
Ipsen telegraphed plans to acquire Epizyme and the FDA-approved Tazverik in June 2022, two years after the med’s clearance in the U.S. as both an epithelioid sarcoma and follicular lymphoma treatment.
Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated ...
Cure rate of 42% estimated in cure modeling; highest rate seen for patients with low Follicular Lymphoma International Prognostic Index scores.
A new statistical analysis of patients with follicular lymphoma, made possible by 15 years of follow-up data from a SWOG and ...
March is the awareness month for colorectal cancer and multiple myeloma. If you’re interested in speaking to experts, contact media@fredhutch.org to schedule interviews. Scientists develop ...
Twenty years. That's how long Robert Oman has been cancer-free, thanks to a clinical trial offered at the University of ...
“[I thought] I had an intolerance to vodka," said Claire Dougherty ...
Tattoos may increase the risk of developing lymphoma and skin cancer, a recent study suggests. "We can see that ink particles accumulate in the lymph nodes, and we suspect that the body perceives them ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results